Aug 17, 2026 08:30AM
Aug 13, 2026 08:30AM
Jul 20, 2026 08:30AM
Jul 20, 2026 08:30AM
Jun 30, 2026 08:45AM
Jun 30, 2026 08:45AM
May 18, 2026 08:45AM Dogwood Therapeutics begins 12-week extension study for pain drug
May 18, 2026 08:45AM
May 14, 2026 08:30AM
May 7, 2026 08:30AM
Apr 23, 2026 09:00AM
Apr 23, 2026 09:00AM
Apr 15, 2026 09:02AM
Apr 15, 2026 09:00AM Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Mar 18, 2026 08:30AM
Feb 2, 2026 08:30AM
Jan 20, 2026 08:38AM
Jan 12, 2026 08:33AM
Jan 12, 2026 08:30AM
Dec 22, 2025 10:15AM
Dec 22, 2025 10:15AM Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dec 2, 2025 08:06AM
Dec 2, 2025 08:00AM
Nov 11, 2025 08:45AM
Nov 6, 2025 08:45AM
Oct 30, 2025 09:15AM
Sep 29, 2025 07:19AM
Sep 29, 2025 07:15AM Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s
Sep 3, 2025 09:15AM
Aug 13, 2025 09:00AM
Aug 7, 2025 01:10PM
Aug 7, 2025 01:08PM
Aug 6, 2025 09:15AM
Jun 3, 2025 09:15AM
May 8, 2025 09:00AM Dogwood Therapeutics Announces First Quarter 2025 Financial Results
May 1, 2025 08:30AM
Apr 23, 2025 06:35AM
Apr 11, 2025 09:15AM
Apr 11, 2025 09:15AM
Apr 3, 2025 09:00AM
Apr 3, 2025 09:00AM
Mar 31, 2025 03:45PM Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar 18, 2025 08:45AM
Mar 18, 2025 08:45AM
Mar 13, 2025 09:02AM
Mar 13, 2025 09:00AM
Mar 12, 2025 08:31AM
Mar 12, 2025 08:30AM
Jan 21, 2025 09:15AM Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
Nov 18, 2024 08:46AM

330,742 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All